Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of CKD-371 in Healthy Subjects
NCT05544214Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-371 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Oct 2022; status: completed.
02
Drugs
CKD-371
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05544214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544214.